solution was diluted to 2M urea with ABC and incubated overnight in the presence of sequencing grade modified trypsin (1:50 w/w) (Promega, Madison, WI) at 37 o C for complete digestion. Subsequently, the peptide mixture was concentrated and desalted using stop and go elution (STAGE) tips as described by Rappsilber and coworkers.
1 Briefly, the acidified peptides were bound on activated C18 reversed phase material fixed in a standard pipettor tip, washed with 0.5% acetic acid and eluted with 80% acetonitrile 0.5% acetic acid. Finally, the acetonitrile buffer was removed using a SpeedVac (Savant DNA 110 SpeedVac; Global Medical Instruments) after which the peptides were dissolved in 0.5% acetic acid for nLC-MS/MS analysis.
C18 Reversed phase LC-MS/MS analysis
The C18 reversed phase nanoflow LC-MS/MS analyses were performed using a Proxeon nanoflow liquid chromatograph (Easy-nLC, Thermo Fisher, Bremen, Germany) coupled online to a 7T linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT Ultra, Thermo Fisher Scientific, Bremen, Germany) as described. 2 Briefly, chromatographic separations were performed using a 15-cm fused silica emitter 
Database searching and result validation
Database searches and validation of results was performed as described 2 . Briefly, the raw data files acquired by the nLC-MS/MS instrument were converted to mascot generic files using DTA supercharge. 3 Peptides and proteins were identified using Mascot software (Mascot 2.2; Matrix Science) to search a local copy of an in-house created pan-genomic B.
pertussis protein database (based on the sequence data as described 4 ) supplemented with known contaminant protein sequences (e.g. Trypsin, LysC and human skin proteins). The following parameters were used: 15 ppm precursor mass tolerance and a 0.5 Da fragment ion mass tolerance. Furthermore, one missed trypsin cleavage was tolerated and carbamidomethylation of cysteines was set as a fixed modification. Variable modifications included oxidation of methionine residues and N-terminal protein acetylation. The Mascot search results were subjected to heuristic iterative protein false discovery rate validation method of Weatherly to achieve a 1% false discovery rate or better. 5 A protein was considered identified when it was detected in at least 3 out of 4 biological replicates for the planktonic condition and 2 out of 3 biological replicates for the biofilm condition.
Exponentially modified PAI (emPAI) scores were calculated as described. Protein ratios were calculated as the weighted average of all respective peptide ratios.
Processing semi-quantitative proteomics data
Protein abundance ratios were generated by IDEAL-Q for each biological replicate relative to mid-exponential sample one and normalized using the median ratio of all proteins quantified.
The normalized ratios were Log2 transformed and used for a One-Way ANOVA with the maximum number of permutations (=34650) to identify proteins that were significantly different (P-value ≤0.05) between the three groups. Proteins that were found to be significantly different based on less than 3 out of 4 biological replicates (or 2 out of 3 biological replicates for the biofilm condition) in one of the groups, were excluded. The Pvalues of all the remaining proteins (both significant and non-significant) were corrected for multiple testing using the FDR method of Storey and Tibshirani to obtain q-values. 8 Proteins with a P-value ≤ 0.05 and a fold change of ≥3 or ≤-3 were considered biofilm-regulated.
Biofilm-regulated proteins were aggregated based on function (main role according to the TIGR B. pertussis genome and B. bronchiseptica database) and subcellular localization (predicted using PSORTb v3.0 9 ) and significant enrichment in a certain class was determined by Fisher's exact test.
Validation proteomic datasets
Proteomics allowed us to identify a total of 749, 729, and 825 proteins in the mid-log, stationary, and biofilm cultures, respectively, representing 21-24% of the predicted total of 3449 protein-coding ORFs in the B. pertussis genome. Of the 887 detected proteins, 645 (73%)
were identified under all growth conditions (Supplementary Table S2 ). Of the 749 proteins identified in the mid-log planktonic samples, 238 (32%) proteins were found only in the cytosolic fraction, 102 (14%) only in the membrane fraction, and 409 proteins (55%) were identified in both fractions. In the stationary planktonic samples, 355 of the 729 proteins (49%)
were identified in both fractions whereas 220 (30%) and 154 (21%) proteins were found uniquely in the cytosolic and membrane protein fraction respectively. Of the 825 proteins identified in the biofilm samples, 222 (27%) proteins were found only in the cytosolic fraction, 129 (16%) only in the membrane fraction, and 474 proteins (57%) were identified in both fractions.
Correct fractionation of the cytosolic and membrane proteins was confirmed using the protein abundance emPAI values of proteins with a strongly predicted cytosolic and outer membrane localization (determined using PSORTb 3.0). This revealed clear enrichment (high emPAI scores) for cytosolic predicted proteins in the cytosol fractions and membranepredicted proteins in the membrane fractions of all samples in both (data not shown).
Furthermore, western blot analysis revealed that the outer membrane protein BP0840 was exclusively present in the membrane protein fraction of all samples (data not shown). This data indicates correct protein fractionation of all samples.
